Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy

BACKGROUND AND PURPOSE: Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. METHODS: Eighty-five patients received perampane...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Neurol
Hlavní autoři: Youn, Song Ee, Kim, Se Hee, Ko, Ara, Lee, Sun Ho, Lee, Young Mock, Kang, Hoon-Chul, Lee, Joon Soo, Kim, Heung Dong
Médium: Artigo
Jazyk:Inglês
Vydáno: Korean Neurological Association 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6031997/
https://ncbi.nlm.nih.gov/pubmed/29971974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3988/jcn.2018.14.3.296
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky